menu
    • menu
    [{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CNTY-104","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Century Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Century Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-102","moa":"CD19\/79b","graph1":"Oncology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Century Therapeutics

    Menu

    Century Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Century Announces Phase 1/2 Trial of iNK Cell Therapy CNTY-101 in Autoimmune Diseases

                            Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, intended for moderate to severe systemic lupus erythematosus.

                            Product Name : CNTY-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : CNTY-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Century Therapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-101

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $60.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Century Therapeutics Expands Autoimmune Pipeline Supported by $60M and Clade Acquisition

                            Details : Century intends to use the net proceeds to support the expansion of CNTY-101, a CD19-targeting iNK cell therapy, currently being evaluated in a clinical trial in B-cell malignancies.

                            Product Name : CNTY-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 04, 2024

                            Lead Product(s) : CNTY-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $60.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-101,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-10...

                            Details : CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived NK cells with a CD19-directed CAR and designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells...

                            Product Name : CNTY-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : CNTY-101,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-101

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

                            Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, administered via Intravenous Infusion, intended for moderate to severe systemic lupus erythematosus.

                            Product Name : CNTY-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 12, 2023

                            Lead Product(s) : CNTY-101

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-104

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,150.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived All...

                            Details : Century will be responsible for discovery and preclinical development of CNTY-104, an iPSC-derived allogeneic cell therapies for hematologic and solid tumors. Bristol Myers Squibb will be responsible for clinical development and commercialization of firs...

                            Product Name : CNTY-104

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $150.0 million

                            October 01, 2022

                            Lead Product(s) : CNTY-104

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,150.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-101,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell ...

                            Details : CNTY-101 is the first allogeneic cell product candidate with six genetic modifications incorporated using sequential rounds of CRISPR-mediated homologous recombination and repair that has received IND clearance by the FDA.

                            Product Name : CNTY-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 25, 2022

                            Lead Product(s) : CNTY-101,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-101,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Century Therapeutics to Present at the SITC 37th Annual Meeting

                            Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch.

                            Product Name : CNTY-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 10, 2022

                            Lead Product(s) : CNTY-101,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Century Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNTY-102

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Century Therapeutics to Present at the ASGCT 25th Annual Meeting

                            Details : CNTY-102 simultaneously target CD19 and CD79b designed to increase depth and durability of response by eliminating effect of CD19 antigen loss that has been observed as factor limiting treatment durability while targeting CD79b.

                            Product Name : CNTY-102

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 05, 2022

                            Lead Product(s) : CNTY-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth